CompletedPhase 2NCT02407678
REP1 Gene Replacement Therapy for Choroideremia
Studying Choroideremia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oxford
- Principal Investigator
- Robert E MacLaren, MB ChB DPhilUniversity of Oxford
- Intervention
- AAV-mediated REP1 gene replacement(genetic)
- Enrollment
- 30 enrolled
- Eligibility
- 18-90 years · MALE
- Timeline
- 2016 – 2021
Study locations (2)
- Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
- Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Collaborators
Moorfields Eye Hospital NHS Foundation Trust · University College, London
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02407678 on ClinicalTrials.govOther trials for Choroideremia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1NCT06460844Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)Ray Therapeutics, Inc.
- RECRUITINGNCT06375239Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal DegenerationRay Therapeutics, Inc.
- ENROLLING BY INVITATIONNCT05158049Longitudinal Study of a Bionic EyeCenter for Eye Research Australia
- ACTIVE NOT RECRUITINGPHASE1NCT04483440Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia4D Molecular Therapeutics
- ENROLLING BY INVITATIONPHASE3NCT03584165Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis PigmentosaNightstaRx Ltd, a Biogen Company
- RECRUITINGNCT01866371High Resolution Retinal ImagingUniversity of Pennsylvania